American Association for Cancer Research
00085472can141030-sup-129547_2_supp_2619819_n7kvmd.png (197.86 kB)

Supplementary Figure S11 from CtBP2 Modulates the Androgen Receptor to Promote Prostate Cancer Progression

Download (197.86 kB)
posted on 2023-03-30, 22:43 authored by Ken-ichi Takayama, Takashi Suzuki, Tetsuya Fujimura, Tomohiko Urano, Satoru Takahashi, Yukio Homma, Satoshi Inoue

Supplementary Figure S11. A model for the functions of CtBP2 in modulating AR signaling in prostate cancer.



The androgen receptor (AR) is the key driver of both early and advanced prostate cancer, making a complete understanding of its regulation important. Here, we report the identification of multiple AR-binding sites in the gene encoding the transcription factor CtBP2 (carboxyl terminal–binding protein), genetic variations of which have been associated with prostate cancer susceptibility. Notably, we found that SNPs in the human CTBP2 gene that were associated with prostate cancer development were correlated with AR-enhancer activity. High CtBP2 expression levels correlated with poor prognosis in patients, whereas CtBP2 silencing reduced tumor growth in a mouse xenograft model of human prostate cancer. Consistent with its function as a transcriptional corepressor, CtBP2 repressed tumor-suppressor genes and AR corepressors in prostate cancer cells, such as NCOR and RIP140, by binding with AR to the promoter enhancers of these genes. Global gene-expression analyses revealed a positive effect on androgen-mediated gene expression, and CtBP2 silencing was found to increase AR interactions with corepressors that limit histone modification. Overall, our results show how CtBP2 contributes to prostate cancer progression by modulating AR and oncogenic signaling. Cancer Res; 74(22); 6542–53. ©2014 AACR.

Usage metrics

    Cancer Research



    Ref. manager